The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.
Researchers discovered that estrogen receptor alpha and glucocorticoid receptor are simultaneously expressed in many endometrial cancers, and may be associated with poor prognosis.
Findings from the GOG-3007 study suggest everolimus plus letrozole might be effective in advanced persistent or recurrent endometrial carcinoma.
Use of oral contraceptives may be beneficial for chemoprevention for a range of women with different baseline cancer risks, according to the results of a new study.
Two studies on Lynch syndrome highlight cancer screening and surveillance opportunities.
Women with increased levels of cadmium, which mimics estrogen in the body, had a higher risk of endometrial cancer, according to a recently published observational study.
The diagnostic benefits of SLN evaluation include an ability to identify the extent of tumor dissemination and the utility of SLN mapping in guiding targeted adjuvant treatment in high-risk patients.
The question that should be posed to those who advocate for lymphadenectomy as a tool to guide the adjuvant therapy of endometrial cancer is: At what cost to the patient is lymphadenectomy performed?
Intentional weight loss can lower the risk of endometrial cancer in postmenopausal women, according to a new study. This was especially true of obese women who lost weight.
Microsatellite instability analysis and immunohistochemistry analysis are highly concordant with regard to testing for mismatch repair deficiency in endometrial cancer.